RxDoctor Payments Data

Yalcin Hacioglu, MD

Interventional Cardiology · Little Rock, ARNPI 1073576625

Payments from drug & device makers

$4,099in general payments, 2019–2025

Across 200 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Medtronic$1K
  • Abiomed$319
  • Abbott$175
  • E.r. Squibb & Sons, L.L.C.$169
  • Merck$163
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$89922%
  • Food & beverage$3,11176%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,099 in reported general payments places this provider in the 30th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$188,825
Medicare patients
798
Services billed
3,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$195,053
EntrestoSacubitril/Valsartan219$175,180
FarxigaDapagliflozin Propanediol115$66,443
MultaqDronedarone Hcl37$29,200
XareltoRivaroxaban13$14,177
JardianceEmpagliflozin18$10,551
Ranolazine ErRanolazine194$7,551
Rosuvastatin Calcium514$3,918
Metoprolol Succinate478$3,801
Clonidine34$2,913
Valsartan182$2,668
Atorvastatin Calcium245$1,504
Amiodarone Hcl80$1,446
Spironolactone298$1,314
Isosorbide Dinitrate46$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$195,053306 claims
NovartisEntresto$1,093$175,180219 claims
AstraZenecaFarxiga$144$66,443115 claims
Sanofi-aventis U.S. LLCMultaq$95$29,20037 claims
Johnson & JohnsonXarelto$43$14,17713 claims
Boehringer IngelheimJardiance$51$10,55118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →